1. Home
  2. SLRC vs SPRY Comparison

SLRC vs SPRY Comparison

Compare SLRC & SPRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SLR Investment Corp.

SLRC

SLR Investment Corp.

HOLD

Current Price

$15.65

Market Cap

803.0M

Sector

Finance

ML Signal

HOLD

Logo ARS Pharmaceuticals Inc.

SPRY

ARS Pharmaceuticals Inc.

HOLD

Current Price

$8.30

Market Cap

833.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLRC
SPRY
Founded
2007
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
803.0M
833.1M
IPO Year
2007
2020

Fundamental Metrics

Financial Performance
Metric
SLRC
SPRY
Price
$15.65
$8.30
Analyst Decision
Hold
Strong Buy
Analyst Count
7
1
Target Price
$15.14
$40.00
AVG Volume (30 Days)
292.9K
1.5M
Earning Date
05-05-2026
05-13-2026
Dividend Yield
10.67%
N/A
EPS Growth
N/A
N/A
EPS
1.70
N/A
Revenue
N/A
$84,278,000.00
Revenue This Year
$1.09
$87.40
Revenue Next Year
N/A
$81.64
P/E Ratio
$9.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.78
$6.66
52 Week High
$17.20
$18.63

Technical Indicators

Market Signals
Indicator
SLRC
SPRY
Relative Strength Index (RSI) 57.87 50.94
Support Level $15.62 $8.05
Resistance Level $16.61 $8.63
Average True Range (ATR) 0.35 0.40
MACD 0.03 0.06
Stochastic Oscillator 61.18 72.22

Price Performance

Historical Comparison
SLRC
SPRY

About SLRC SLR Investment Corp.

SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.

About SPRY ARS Pharmaceuticals Inc.

ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.

Share on Social Networks: